VBL Therapeutics to Participate in the Jefferies Healthcare Conference

3 years ago

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage…

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

3 years ago

THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted…

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

3 years ago

Funding Enables Evaluation of PURION® Processed Placental Tissue as an Innovative Approach in the Management of Acute Military-Related Injuries, Addressing…

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

3 years ago

- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31,…

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

3 years ago

ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Technology

3 years ago

iFuse Bedrock Granite iFuse Bedrock GraniteSANTA CLARA, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based…

Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO

3 years ago

-- Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy…

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

3 years ago

LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and…

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

3 years ago

BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression…

Nasdaq Confirms Continued Listing of Eargo Stock

3 years ago

SAN JOSE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device…